Clinical summary

Science icon

Thousands of clinical trial participants and customers have reported significant improvement in their vision performance by two lines on the visual acuity eye chart, and 100% increase in contrast sensitivity, on average.

  • Polat et al. studied 54 adult amblyopic patients who were randomized to amblyopic NVT treatment or a placebo vision-training program. Pretreatment visual acuity in both study arms was 0.42 logMAR, and this improved by 2.5 lines to 20/30 in the CRT treatment group, with no improvement in the control group. This increase in acuity was corroborated by a commensurate increase in CSF to within the normal range. These improvements in acuity and CSF were sustained after 12 months.
  • Tan et al. reported mean improvement of 2.8 logMar lines in distance unaided visual acuity (UAVA) for 55 low myopes and mean improvement of 1.6 logMar lines in near UAVA for the 41 presbyopes (age 41-55 year old) after completion of the NVT training. The improvements were shown to be retained for at least
    12 months.
  • Tan et al. conducted a randomized controlled trial evaluating the efficacy of NVT in low myopia. The interim results presented by Tan et al, at Asia ARVO 2007 confirmed that statistically significant difference in unaided visual acuity between the masked treatment groups and suggested on completion of the NVT was likely to provide the definitive evidence of efficacy and safety of NVT treatment in improving visual acuity and contrast sensitivity function in adult low myopes. The results of this study correlate well with NVT reported commercial results – mean improvement of 2.6 logMar lines of distance uncorrected visual acuity for low myopes, 2.0 logMar lines near unaided visual acuity for early presbyopes.
  • Durrie et al. evaluated seventeen patients with low myopia (up to -1.75D) and 21 patients with early presbyopia (up to +2.50D Add) in 2 clinical sites who underwent NVT. Eleven myopic and 18 presbyopic patients underwent NVT while 9 patients performed visual examinations only serving as a control group. Researchers found the low myopia treatment group achieved a mean improvement of 2.2 logMAR lines in UAVA. CSF improved at all spatial frequencies. In this arm of the study the control patients did not shown any significant change in vision. The early presbyopia treatment group achieved a mean improvement of 2.2 logMAR lines in near UAVA. Near UCSF also improved at all spatial frequencies. The control patients in this arm have not shown any significant change in vision. Additionally, the mean refractive error in all groups remained unchanged after treatment.
  • Lim et al. reported a single case of NVT for the treatment low myopic regression five years after myopic LASIK. The patient improved 2.8 lines in the right eye and 1.6 lines in the left eye following NVT.
  • Durrie et al. conducted a prospective, randomized, multicenter placebo controlled study comparing CRT after LASIK (“NeuroLASIK”) to sham treatment (video game) following LASIK in 98 eyes. Researchers found 0.8 Snellen lines of UAVA and 79% improvement in contrast sensitivity in the treatment group relative to a 0.28 line improvement and 52% improvement in CSF in the control group. Patients who were worse than 20/20 after LASIK improved 1.56 Snellen lines of UAVA and 90% improvement in CSF with NVT relative to the 0.34 lines and 47% CSF improvement in the control group. The results suggested that patients who had worse vision improved more and that perhaps there is a cortical limit to how much a patient can improve.

The following is a list of clinical studies conducted with the Vision Improvement Program products:

Clinical Condition Tested

The following is a list of eye doctors and eye institutes that tested and validated the Vision Improvement Program:

Eye Doctors

Contact Us

Talshir Medical Technologies LTD
Hama’ayan Street 2, Modi’in 7177871, Israel
USA Office: +1.785.856.0417 | Main Office: +972.77.212.3272

info@revitalvision.com
Contact background